Document Detail

Intravitreal triamcinolone and elevated intraocular pressure.
MedLine Citation:
PMID:  10641903     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To ascertain whether intravitreal triamcinolone given for subretinal neovascularization is associated with an ocular pressure rise. METHODS: A total of 113 patients with angiographically proven subretinal neovascularization were enrolled into a prospective study of the effects of intravitrea triamcinolone. Intraocular pressure was one of the parameters studied. RESULTS: Approximately 30% of the study group developed a significant rise (> or =5 mm Hg) in intraocular pressure above baseline during the first 3 months. CONCLUSIONS: Patients considering this form of treatment should be fully informed of the known risks of intraocular injections of steroids.
R J Wingate; P E Beaumont
Related Documents :
9823343 - Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in ...
9537793 - Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other...
10226263 - Serum cortisol in the white-coat phenomenon.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Australian and New Zealand journal of ophthalmology     Volume:  27     ISSN:  0814-9763     ISO Abbreviation:  Aust N Z J Ophthalmol     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-02-02     Completed Date:  2000-02-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8505423     Medline TA:  Aust N Z J Ophthalmol     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  431-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fluorescein Angiography
Fundus Oculi
Glucocorticoids / adverse effects*,  therapeutic use
Intraocular Pressure / drug effects*
Macular Degeneration / complications
Ocular Hypertension / chemically induced*
Prospective Studies
Retinal Neovascularization / drug therapy*,  etiology
Risk Factors
Treatment Outcome
Triamcinolone Acetonide / adverse effects*,  therapeutic use
Vitreous Body
Reg. No./Substance:
0/Glucocorticoids; 76-25-5/Triamcinolone Acetonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In vitro potency and stability of fortified ophthalmic antibiotics.
Next Document:  Spontaneous suprachoroidal haemorrhage in a patient receiving low-molecular-weight heparin (fraxipar...